Corresponding Author

Asmaa Ameen Ghareeb

Document Type

Research Article


Backgrounds: COVID-19, a new health challenge, can be diagnosed by many laboratory biomarkers. Biomarkers became valuable for prognosis; identifying the severity and mortality of the disease in COVID-19 patients. This study aims to determine the association of clinical, demographics, and laboratory biomarkers (CRP, D-dimer, lymphocyte, and platelet) with the severity and mortality of COVID-19. Methods: Between June 1st and November 1st, 2020, 34 healthy controls and 104 COVID-19 cases were enrolled in this study. SARS-CoV-2 infection was confirmed using the real-time RT-PCR technique. All cases were analyzed for clinical, epidemiological, and laboratory biomarkers. COVID-19 cases were regrouped into mild (n=40), moderate (n=32), and severe (n=32) groups depending on the severity of the disease; it was also re-categorized into survivor (n=85) and non-survivor (n=19) groups depending on mortality. After collecting blood from participants, hematological parameters (lymphocyte and platelet) and other biomarkers (CRP and D-dimer) were measured by colter and Cobas c111, respectively. Results: For age categories and comorbidities, Statistical significance was found among COVID-19 groups. Regarding ABO, Rh, and gender, a non-significant difference was found among groups of COVID-19 patients. Cough and headache i the most common symptom in our population. SpO2 depressed more significantly in severe and moderate groups than in mild groups. Severe and moderate groups exhibit higher CRP, D-dimer, and lymphocyte percentages than control while there was a non-significant change for platelets and absolute lymphocyte counts among studies groups. All studied laboratory biomarkers were higher in non-survivors than in survivor COVID-19 groups. A significant correlation was found between D-dimer and other laboratory biomarkers. Conclusion: Gender, ABO, and Rh were not associated but age and comorbidities were associated with the severity of COVID-19. All studied laboratory biomarkers were associated with mortality.


COVID-19, mortality, laboratory biomarkers, and SARS-CoV-2.

Publication Date